Previous 10 | Next 10 |
84% of PH-HFpEF patients responded to levosimendan based on prespecified criteria in the initial open-label lead-in phase Levosimendan improved cardiovascular hemodynamics and exercise capacity in PH-HFpEF patients Levosimendan produced a significant improvement in 6...
Tenax Therapeutics (TENX) announced the retirement of three members of its board including the chairman Ronald R. Blanck as part of what the company called its ‘Board refreshment program.’The retirement of Dr. Blanck, Gregory Pepin, and Chris A. Rallis with effect as of the...
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that Ronald R. Blanck, D.O., Gregory Pepin and Chr...
Tenax Therapeutics (TENX): FY GAAP EPS of -$1.33 misses by $0.49.Cash, cash equivalents and marketable securities totaled $6.7 million as of December 31, 2020, compared with $5.4 million as of December 31, 2019.Shares -3.16%.Press Release For further details see: Tenax Therapeutics EPS ...
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the year ended December 31, 2...
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced that management will present a company overview and hold virtual invest...
New Board appointments strengthen Tenax with world-class expertise in cardiovascular drug development, commercial strategy, and business development New Directors will provide significant guidance as Tenax is poised to advance its two leading drug candidates into late-stage ...
Senseonics Holdings (SENS) -16% after raising size of stock offering.Global Ship Lease (GSL) -14% after announcing public offering.Globalstar (GSAT) -13% after Morgan Stanley cuts to underweight on valuation.Broadwind (BWEN) -13% after guiding Q4 revenu...
-Conference to be held at 4:30 pm EST on January 21, 2021- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that it will host an investor conf...
Gainers: Aclaris Therapeutics (ACRS) +184%.Gritstone Oncology (GRTS) +111%.Gevo (GEVO) +76%.Senseonics (SENS) +72%.TransEnterix (TRXC) +62%.Dare Bioscience (DARE) +57%.ENDRA Life Sciences (NDRA) +41%.Pennsylvania Real Estate Investment Trust (PEI) +41%.Tenax Therapeutics (TENX)...
News, Short Squeeze, Breakout and More Instantly...
Tenax Therapeutics Inc. Company Name:
TENX Stock Symbol:
NASDAQ Market:
Tenax Therapeutics Inc. Website:
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent ...
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF Provides U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond ...